The humoral immune response after acute infection with HIV-1 is delayed and ineffective. The HIV-1 envelope protein gp120 binds to and signals through integrin a 4 b 7 on T cells. We found that gp120 also bound to and signaled through a 4 b 7 on naive B cells, which resulted in an abortive proliferative response. In primary B cells, signaling by gp120 through a 4 b 7 resulted in increased expression of the immunosuppressive cytokine TGF-b1 and FcRL4, an inhibitory receptor expressed on B cells. Coculture of B cells with HIV-1-infected autologous CD4 + T cells also increased the expression of FcRL4 by B cells. Our findings indicated that in addition to mediating chronic activation of the immune system, viral proteins contributed directly to HIV-1-associated B cell dysfunction. Our studies identify a mechanism whereby the virus may subvert the early HIV-1-specific humoral immune response.
During the course of infection with HIV-1, persistent viral replication leads to a gradual and progressive loss of CD4 + T cells together with an aberrant, generalized and chronic activation of the immune system. That aberrant activation of the immune system affects the viability, subset distribution, phenotype and function of almost all the major hematopoietic cell lineages 1 . Among the cell subsets affected are B cells, which exhibit numerous abnormalities that can be attributed to HIV-1-mediated chronic activation of the immune system 2, 3 . B cells isolated from viremic HIV-1-infected people spontaneously secrete large amounts of immunoglobulins, respond poorly to B cell stimuli and exhibit impaired costimulatory functions [4] [5] [6] . Those functional defects have also been associated with perturbation in the distribution and relative proportions of B cell subpopulations in vivo 7 . In viremic patients with advanced disease caused by infection with HIV, the peripheral blood contains an expanded population of immature and/or transitional B cells, a population generally associated with lymphopenia 8, 9 . In addition, such patients manifest an expanded population of tissue-like CD21 lo memory B cells in their blood with atypically high expression of the inhibitory immunoglobulin A (IgA) receptor FcRL4, along with other inhibitory receptors 10, 11 . Of note, that abnormal B cell subpopulation shows enrichment for HIV-1-specific B cells. Consistent with their high FcRL4 expression 12 , those cells proliferate poorly in response to B cell stimuli. Their presence in the blood is closely linked to ongoing viral replication, because their frequency decreases after the initiation of antiretroviral therapy 13 .
Several studies have reported that defects in the humoral immune response are already present during acute infection with HIV-1. For example, memory B cells in gut-associated lymphoid tissue (GALT) from acutely infected people secrete autoreactive antibodies. Additionally, follicular damage and/or germinal center loss in GALT is seen in the terminal ileum and Peyer's patches soon after infection 14, 15 . Most notably, the initial HIV-specific antibody response is delayed and can be detected in plasma only 2-5 weeks after transmission [16] [17] [18] [19] [20] . In contrast to antibodies to other viruses 16, 21, 22 , autologous neutralizing antibodies to HIV-1 do not become detectable until approximately 12 weeks after transmission, and the appearance of broadly neutralizing antibodies is greatly delayed and they are present in only approximately 20% of HIV-infected people 17 . The mechanisms that underlie those delayed antibody responses are not known, but identifying them is probably essential for understanding the evolution of broadly neutralizing antibodies to HIV-1. Identifying those mechanisms is a central issue relevant to the design and development of vaccine immunogens able to elicit broadly neutralizing antibodies. Here we identified a previously unknown mechanism by which the HIV-1 envelope protein gp120, by engaging the integrin α 4 β 7 , exerted a profoundly negative effect on B cell function.
RESULTS

B cells express a 4 b 7 and bind gp120
We isolated human B cells from peripheral blood mononuclear cells from human donors and assessed their baseline expression of α 4 β 7 by flow cytometry with an antibody to the β 7 chain of α 4 β 7 (FIB504) and an antibody specific for the heterodimer α 4 β 7 (Act-1). We found that human peripheral blood B cells constitutively expressed α 4 β 7 (ref. 23) (Fig. 1a) . We did note donor variability, as cells from some donors had higher α 4 β 7 expression than that on cells from other donors (Fig. 1b) , in both frequency and mean density. To verify that the α 4 β 7 on peripheral blood B cells functioned as an integrin, we assessed whether it was able to bind its natural ligand, the adhesion molecule MAdCAM-1. We found substantial binding of soluble MAdCAM-1 to B cells that expressed α 4 β 7 , which decreased in the presence of the monoclonal antibody (mAb) 2B4, which binds to the α 4 chain of α 4 β 7 and is known to compete with MAdCAM-1 for binding to α 4 β 7 (Fig. 1c) .
Having established that freshly isolated human blood B cells expressed functional α 4 β 7 , we assessed whether recombinant gp120 of HIV-1 also bound to α 4 β 7 on freshly isolated primary B cells. Because divalent cations regulate the activation state of the integrin and thereby influence the binding of gp120 to α 4 β 7 , we included divalent cations in the binding buffer 24 . The gp120 in the binding assay was derived from an early viral isolate of HIV-1 subtype A/C (R66M). That gp120 bound to B cells, and there was much less binding after removal of the divalent cations from the buffer (Fig. 1c) . The gp120 of HIV R66M bound significantly better to B cells with higher expression of α 4 β 7 than to those with lower expression of α 4 β 7 (Fig. 1b) . Two specific mAbs to α 4 also inhibited the binding of gp120 to α 4 β 7 on B cells, although not always to baseline amounts (Fig. 1b-d) . These findings indicated that most of the binding of gp120 to B cells was mediated by α 4 β 7 , although the possibility of other interactions could not be excluded. In separate experiments, we assessed several gp120 envelope proteins from HIV-1 subtypes A, B and C; all exhibited reactivity for α 4 β 7 , but to varying degrees (Fig. 1d) . Other studies have reported that gp120 binds to human B cells. A published report has found that gp120 binds to C-type lectins expressed on activated human B cells and induces immunoglobulin class switching and increased expression of the cytidine deaminase AID 25 . However, ours is the first study to our knowledge to demonstrate binding of gp120 to freshly isolated B cells in the absence of activation. Together our results indicated that most peripheral blood B cells expressed α 4 β 7 and that gp120 proteins from each of the major subtypes of HIV bound to B cells through an interaction involving α 4 β 7 .
T cell-independent stimulation is suppressed by gp120 Naive and effector lymphocytes use α 4 β 7 to extravasate from the blood to gut mucosal tissues by interacting with MAdCAM-1 on the endothelium 26 . In addition, α 4 β 7 functions as a costimulatory receptor on GALT B cells, where it engages MAdCAM-1 on follicular dendritic cells in Peyer's patches and mesenteric lymph nodes 27, 28 . gp120 can transduce signals through α 4 β 7 on primary CD4 + T cells 24 . Having shown that gp120 also bound α 4 β 7 on primary B cells, we assessed whether gp120 induced signal transduction through α 4 β 7 on B cells, resulting in altered function. We labeled purified B cells with the division-tracking dye CFSE and then treated them with antibody to IgM (anti-IgM), along with the Toll-like receptor 9 (TLR9) ligand CpG (which together mimic T cell-independent activation of B cells), in the presence of either a gp120 protein that bound strongly to α 4 β 7 (gp120 from HIV R66M) (Fig. 1b-d) or, as a control, a second gp120 protein with minimal binding to α 4 β 7 (gp120 from HIV isolate 92Th14-12) (Fig. 1d) . After 4 d, we stained cells with antibody to the signal-transduction receptor CD19 and examined by flow cytometry their dilution of CFSE. As expected, anti-IgM plus CpG induced a strong proliferative response, with only ~16% of the cells lacking dilution of CFSE. Some cells exhibited eightfold dilution of CFSE (Fig. 2a, left) . The inclusion of gp120 from HIV R66M (which had high reactivity for α 4 β 7 ) along with anti-IgM plus CpG led to an abortive proliferative response, while exposure to gp120 from HIV 92Th14-12 (which had minimal reactivity with α 4 β 7 ) had no effect (Fig. 2a) . 45% of the cells exposed to gp120 from HIV R66M did not undergo CFSE dilution, and most of the cells that responded underwent only twofold dilution, while the CFSE-dilution pattern of the cells treated with gp120 from HIV 92Th14-12 resembled that of the control cells activated with anti-IgM plus CpG alone (Fig. 2a) . The addition of α 4 β 7 -reactive gp120 resulted in significantly less proliferation, as indicated by the change in division index (Fig. 2b) . Additionally, gp120 from the HIV isolate R880F, another envelope protein with a high reactivity for α 4 β 7 (Fig. 1c) , inhibited B cell proliferation in a dose-dependent manner (Fig. 2c) .
Despite the block in the proliferation of cells stimulated in the presence of α 4 β 7 -reactive gp120, light scatter revealed an increase in the size of B cells consistent with cellular activation (Fig. 2d) , with only a minor increase (~10%) in cell mortality after 72 h. That indicated that gp120 was not blocking early stages of cell division. To address this issue, we treated B cells with anti-IgM plus CpG, with or without gp120, then stained the cells with propidium iodide and analyzed them by flow cytometry. We found that a large fraction of cells entered the G1-S phases of the cell cycle but were blocked from entering G2-M (Fig. 2e) . Thus, gp120 did not act on B cells at the early stages of cell cycle but inhibited proliferation at the G1-S phase, with a minor effect on survival.
gp120-mediated gene expression in B cells
To better understand the mechanisms by which the α 4 β 7 -gp120 interaction affected primary human B cells, we exposed human B cells to various gp120 proteins or a mock protein preparation, then assessed the cells by oligonucleotide microarray analysis. In the first set of experiments, we used two closely related gp120 proteins isolated from a single patient 29 . Z205F 0M gp120, which bound strongly to α 4 β 7 , was derived from a patient infected with HIV-1 subtype C within the first month of infection ('0M'). Z205F 38M gp120 was isolated from the same patient 38 months after infection ('38M') and showed low but detectable α 4 β 7 reactivity 30 . As expected, those two envelope proteins bound peripheral blood B cells differently, in an α 4 β 7 -dependent manner (Fig. 3a) . We then treated freshly isolated unstimulated B cells from healthy donors with each of the two gp120 proteins and measured the gp120-mediated transcriptional pattern at three time points (0.5, 3 and 6 h). Hierarchical clustering of sample groups showed that the affinity of gp120 for α 4 β 7 was a strong factor that drove gene expression; after exposure to Z205F 0M gp120 (strong α 4 β 7 reactivity), the gene-expression profiles of cells from different donors clustered together (Fig. 3b) . We further subclustered the sample groups on the basis of time and identified two major clusters: cluster 1 included upregulated genes, and cluster 2 was composed of downregulated genes (Fig. 3b) . Approximately 500 genes in primary B cells were affected by treatment with gp120 (Fig. 3b) . The degree of modulation in the two main clusters seemed to be proportional to the α 4 β 7 reactivity of the gp120 used (Fig. 3b) . Most of the genes modulated by treatment with gp120 encoded proteins associated with chemotaxis, regulation of apoptosis, regulation of lymphocyte proliferation and immunological-inflammatory responses ( Table 1) .
Among the various induced genes identified by this microarray analysis were genes that encode cytokines and chemokines, including tumor-necrosis factor (TNF), interleukin 1β (IL1B) and transforming growth factor-β1 (TGF-β1; TGFB1) ( Table 1 ). In addition to modulating 
expression of TGFB1 itself, treatment with gp120 modulated the expression of genes encoding several components of the TGF-β pathway, including SMAD6 (SMAD6) and SMAD7 (SMAD7) ( Table 1) . gp120 also affected a variety of genes that encode molecules involved in the activation and differentiation of B cells, including the costimulatory molecules CD86 (CD86), CD38 (CD38) and CD83 (CD83), the costimulatory receptor CD27 (CD27), the transcriptional repressor Bcl-6 (BCL6), the G protein-signaling regulator RGS1 (RGS1) and the kinase inhibitor p21 (CDKN1A) ( Table 1) . Of note, we also detected an increase in the expression of ITGA5, which encodes the α-integrin subunit that forms the fibronectin-binding heterodimer 31 ( Table 1) . Another gene upregulated by the treatment of B cells with gp120 was FCRL4, which encodes the inhibitory receptor FcRL4 expressed on a subset of memory B cells and is upregulated in the peripheral blood of HIV-1-infected people and in the peripheral blood of people with chronic malaria 10,32-34 ( Table 1) . To verify the altered gene-expression profile identified by microarray analysis, we used real-time PCR to 'cross-check' selected genes of interest, including IL1B, TNFAIP6, TGFB1, SMAD6, SMAD7, ITGA5 and FCRL4 (Fig. 3c) . Of note, the degree of gene upregulation detected by PCR analysis was consistently higher than that observed in our microarray analysis, which indicated that the latter method underestimated the actual changes in transcription. These data indicated that the exposure of peripheral blood B cells to gp120 altered the transcriptional pattern of many genes encoding molecules involved in inflammation and B cell function. Furthermore, expression of those genes was altered more by gp120 with a relatively high affinity for α 4 β 7 than by gp120 with low α 4 β 7 reactivity.
gp120-mediated gene expression in activated B cells
Next we did an analysis similar to that described above, but stimulated the B cells with a T cell-independent inductive signal in the presence or absence of gp120. We used the same two envelope proteins we used in the initial binding assays: gp120 from HIV R66M (with high affinity for α 4 β 7 ) and gp120 from HIV 92Th14-12 (with negative or low affinity for α 4 β 7 ) (Fig. 4a) . We obtained B cells from healthy donors, treated the cells with gp120 and analyzed gene expression 6 h later. We identified >500 mRNA transcripts modulated by treatment with gp120 (Fig. 4b) . Proteins encoded by those were grouped in the following categories: regulation of apoptosis, immune response, leukocyte proliferation, regulation of lymphocyte activation and differentiation ( Table 2) . Treatment of the activated B cells with gp120 altered the transcription pattern of many of the same genes we had noted in the first microarray with unstimulated B cells. Those included TGFB1, SMAD7 and CDKN1A (which encodes p21) ( Table 2) , as well as genes encoding molecules involved in the TGF-β pathway, including the type II receptor for bone-morphogenic protein (BMPR2), the signaling inhibitor SOCS1 (SOCS1) and the TGF-β-binding protein LTBP3 (LTBP3) (data not shown). FCRL4 was another gene that seemed to be upregulated in both the first analysis and second analysis (Fig. 4c) . Of note, activation alone induced a fourfold (Fig. 4c) . However, the inclusion of gp120 from HIV R66M increased the abundance of FCRL4 mRNA an additional eightfold, while the treatment of cells with the gp120 from HIV 92Th14-12 had no effect (Fig. 4c) .
gp120-mediated modulation of CD80 and FcRL4 expression
An effective humoral response requires cognate B cell-T cell interactions. In this context, one of the key costimulatory interactions involves the costimulatory receptors CD80 and CD86 on activated B cells and the coreceptor CD28 on responder CD4 + T cells 35 .
In vitro-stimulated B cells from HIV-infected viremic people upregulate their expression of CD80 and CD86 poorly relative to cells from healthy donors 6 , and germinal center B cells of HIV-infected people have low CD80 expression but relatively normal CD86 expression 36 . As our microarray analysis revealed a reduction in CD86 mRNA expression after treatment with gp120 (Tables 1 and 2) , we used flow cytometry to assess surface expression of CD80 and CD86 after T cell-independent stimulation in the presence or absence of gp120. When we added the gp120 from HIV R880F, which efficiently bound α 4 β 7 , the stimulated B cells poorly upregulated their surface expression of CD80 relative to that of B cells stimulated in the absence of gp120 or in the presence of a weak binding variant of gp120 (from HIV 92Th14-12) (Fig. 5a) . We assessed in parallel, over a time course, gp120 proteins that bound α 4 β 7 with high affinity (gp120 from HIV isolate R880F) or intermediate affinity (gp120 from HIV isolate AN1) and found that each reduced the induction of CD80 expression (Fig. 5b) . That gp120-mediated effect on surface expression was specific for CD80, as we unexpectedly detected no change in the surface expression of CD86 (Fig. 5c) , despite the reduced expression of CD86 mRNA (Tables 1 and 2) .
FcRL4 is an IgA receptor whose expression on B cells is associated with inhibition of signaling via the B cell antigen receptor 11, 12, 37 . In healthy people, FcRL4 + B cells are localized mainly to mucosal tissues and mesenteric lymph nodes and are rarely found in peripheral blood, peripheral lymph nodes or the spleen 32, 38 . However, as noted above, in HIV-1-infected viremic people, FcRL4 + B cells appear in the peripheral blood 10 . Because gp120 increased FCRL4 mRNA in B cells, we determined whether the increased surface expression of FcRL4 associated with viremia might be due to the interaction of B cells with the viral envelope. We activated peripheral B cells with T cell-independent stimulation with or without gp120 and measured surface expression of FcRL4 by flow cytometry. As expected, we detected no basal expression of FcRL4 on freshly isolated peripheral blood B cells (at 0 h; Fig. 6a) , the majority of which were circulating CD27 − naive B cells (Supplementary Fig. 1) . Consistent with our microarray analysis, at 24 h after T cell-independent stimulation, peripheral B cells exhibited measurable FcRL4 expression on the cell surface; expression then decreased such that by 72 h, FcRL4 expression was similar to that of unstimulated cells (Fig. 6a) . To our knowledge, this is the first demonstration of upregulation of FcRL4 expression by T cellindependent stimulation. The addition of α 4 β 7 -reactive gp120 (from HIV R880F) together with T cell-independent stimulation increased the early induction of FcRL4 even further (mean increase, 80%; range of increase, 27-221%; seven experiments with seven independent donors). Moreover, the inclusion of gp120 resulted in prolonged expression of FcRL4, such that the elevated expression was maintained at 72-96 h after treatment (Fig. 6b) . When we stimulated B cells in the presence of gp120 with intermediate affinity for α 4 β 7 (gp120 from HIV AN1), FcRL4 expression was induced and sustained, but to a lower degree (Fig. 6c) . We then assessed FcRL4 expression relative to the proliferative status through the use of CFSE-labeled B cells. At 96 h after T cell-independent stimulation alone, most B cells showed the expected proliferation (Fig. 6d) , but as reported above (Fig. 6a,b) , at 72-96 h, there was little detectable surface expression of FcRL4 (Fig. 6d) . In contrast, after 96 h, most B cells stimulated in the presence of the highly α 4 β 7 -reactive gp120 (from HIV R880F) did not proliferate but did express FcRL4 (Fig. 6d,e) . When we used gp120 with intermediate α 4 β 7 reactivity (gp120 from HIV AN1), both the inhibition of proliferation and the upregulation of FcRL4 were less pronounced (Fig. 6d) . High FcRL4 expression on the surface of gp120-treated cells correlated with an inability of those cells to divide in response to T cell-independent stimulation. Together these data indicated that treatment of B cells with gp120 increased the expression of FcRL4 and limited the proliferative expansion of B cells in an α 4 β 7 -dependent manner.
Infected T cells induce B cell FcRL4
We next investigated whether HIV-1 replication in CD4 + T cells would induce surface expression of FcRL4 on bystander B cells. We obtained CD4 + T cells from an HIV-1-negative donor, stimulated npg them with IL2, anti-CD3 and retinoic acid and then infected them with chemokine receptor CCR5-tropic HIV. After 7 d, we activated freshly isolated autologous B cells and added those cells to the culture containing the infected CD4 + T cells. We also generated autologous B cell-T cell cocultures with uninfected T cells, as a control. We assessed infection efficiency by enzyme-linked immunosorbent assay of the HIV-1 core antigen p24 and by staining cell surfaces with mAb A32 (anti-gp120) (Fig. 6f) . We then assessed FcRL4 expression by flow cytometry 48 h after initiation of the coculture. By 48 h, ~40% of the CD19 + B cells cultured with infected T cells had high expression of FcRL4, compared with only ~20% of the B cells in the control cocultures with uninfected T cells (Fig. 6g) . Of note, the induction of FcRL4 expression in the T cell-B cell cocultures was somewhat variable for cells from different donors (Fig. 6h) . Thus, both treatment with gp120 and coculture with HIV-1-infected CD4 + T cells induced FcRL4 expression on peripheral blood B cells.
gp120-mediated TGF-b1 secretion and FcRL4 expression
By microarray analysis, we found that treatment with gp120 led to increased expression of TGFB1 mRNA, which we confirmed by RT-PCR ( Tables 1 and 2 and Fig. 3 ). TGF-β1 is produced by activated lymphocytes and can inhibit B cell proliferation 39 . Because gp120 suppresses proliferation induced by a T cell-independent inductive signal, we sought to determine whether this effect was mediated by TGF-β1. We first determined whether gp120 induced the secretion of active TGF-β1 from activated B cells. We found that B cells obtained from 
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A r t i c l e s decreased after 72 h (Fig. 8c) . The addition of α 4 β 7 -reactive gp120 further induced, and sustained over time (96 h), FcRL4 expression and suppressed CD80 expression (Fig. 8d) , as we had observed for T cell-independent stimulation (Figs. 5 and 6) . The TGF-β1-neutralizing mAb reversed the effect of gp120 on the expression of FcRL4 and CD80, while the inclusion of TGF-β1 alone recapitulated the effect of gp120 (Fig. 8d) . When we stimulated CFSE-labeled B cells with a T cell-dependent inductive signal in the presence of α 4 β 7 -reactive gp120 (from HIV R66M), a large fraction (45%) of B cells had not proliferated by 96 h (Fig. 8e,f) . The inclusion of the TGF-β1-neutralizing mAb restored the proliferation (Fig. 8e) , whereas the inclusion of TGF-β1 alone recapitulated the effect of gp120 (Fig. 8e,f) . We concluded that the effect of gp120 on the T cell-dependent stimulation of B cells was similar to its effect on T cell-independent stimulation and that this effect was mediated by TGF-β1. Finally, we sought to determine whether treatment with gp120 would affect T cell-independent or T cell-dependent stimulation of memory B cells in a manner similar to its effect on naive B cells. We obtained CD27 + B cells from fresh peripheral blood mononuclear cell preparations by bead selection. We observed donor-to-donor variability in β 7 expression (Supplementary Fig. 2a) . The α 4 β 7 -reactive gp120 from HIV R66M modestly reduced the surface expression of CD80 when included in the T cell-independent stimulation of CD27 + memory B cells (Supplementary Fig. 2b) . We observed a similar modest effect for T cell-dependent stimulation ( Supplementary  Fig. 2b ). As in naive B cells, the surface expression of CD86 was not reduced (Supplementary Fig. 2c) . However, for both T cellindependent stimulation and T cell-dependent stimulation, the α 4 β 7 -reactive gp120 from HIV R66M did upregulate surface expression of FcRL4 (Supplementary Fig. 2d ). When we stimulated CFSE-labeled B cells with a T cell-independent inductive signal in the presence of the α 4 β 7 -reactive gp120 from HIV R66M, we found that ~20% of B cells did not proliferate by 96 h (Supplementary Fig. 2e,f) . When we stimulated CFSE-labeled B cells with a T cell-dependent inductive signal in the presence of gp120 from HIV R66M, we found that only ~5% of the cells failed to proliferate by 96 h healthy donors, treated with a T cell-independent stimulus and cultured with α 4 β 7 -reactive gp120 produced significantly more TGF-β1 in culture supernatants than did cells that were only activated (Fig. 7a) . That observation, along with the known roles of TGF-β1 in promoting switching to IgA 40, 41 and FcRL4 as an Fc receptor for IgA 11 , prompted us to investigate whether TGF-β1 might substitute for gp120 as an inductive signal for FcRL4 expression. We found that TGF-β1 was able to recapitulate the gp120-mediated induction of FcRL4 surface expression (Fig. 7b) , which suggested that gp120 induced FcRL4 via the induction of TGF-β1. To determine whether that was the case, we activated B cells with a T cell-independent stimulus and treated them with gp120 in the presence or absence of anti-TGF-β1 and found that the inclusion of anti-TGF-β1 reversed the gp120-mediated induction of FcRL4 expression and downregulated CD80 surface expression (Fig. 7b) . To determine if the gp120-mediated inhibition of the proliferative response was also linked to induction of TGF-β1, we included a TGF-β1-neutralizing mAb in a proliferation assay of CFSE-labeled activated B cells. The inclusion of the TGF-β1-neutralizing mAb restored the proliferative ability of stimulated B cells in the presence of gp120 (Fig. 7c) . The addition of either α 4 β 7 -reactive gp120 or TGF-β1 resulted in significant inhibition of B cell proliferation, as assessed by changes in the division index (Fig. 7d) . We concluded that TGF-β1 had a central role in both the gp120-mediated induction of FcRL4 expression and the gp120-mediated inhibition of B cell proliferation. These results revealed a previously unknown relationship between TGF-β1 and surface expression of FcRL4.
T cell-dependent stimulation is suppressed by gp120
We next sought to determine whether gp120 affected the T celldependent proliferation of B cells. We modeled such proliferation by stimulating B cells with anti-IgM plus CpG and mAb to CD40 (ref. 42 ). We first investigated whether α 4 β 7 -reactive gp120 affected cell surface expression of CD80 and CD86. The T cell-dependent stimulation strongly upregulated the surface expression of both CD80 and CD86 (Fig. 8a,b) and, as noted after T cell-independent stimulation, the addition of gp120 suppressed the induction of CD80 expression but not that of CD86 (Fig. 8a,b) . The T cell-dependent stimulation also upregulated the surface expression of FcRL4 after 24 h, which npg ( Supplementary Fig. 2g,h) . Treatment of CD27 + memory B cells resulted in 5-20% inhibition of proliferation, compared with 45-65% inhibition of proliferation for naive B cells treated similarly (Supplementary Fig. 2) . We concluded that the α 4 β 7 -reactive gp120 affected the responses of memory B cells to T cell-independent and T cell-dependent in a relatively modest way compared with the suppressive effect we observed for naive B cells.
DISCUSSION
In this report, we have shown that binding of gp120 to human B cells via integrin α 4 β 7 interfered with the activation and proliferation of B cells. Also, gp120 induced an α 4 β 7 -dependent pattern of gene expression in B cells that suggested an inhibitory effect. These findings indicated a potentially important mechanism by which HIV-1 might directly impair B cell function. Specifically, gp120 impaired B cell function by activating inhibitory pathways that resulted in the production of TGF-β1, induction of FcRL4 expression and low surface expression of CD80.
It is well established that TGF-β1 inhibits the activation and proliferation of B cells, both of which are essential for an efficient B cell response 39, 43 . Moreover, overproduction of TGF-β1 has been linked to lymph node fibrosis in people infected with HIV and monkeys infected with simian immunodeficiency virus [44] [45] [46] . Thus, the induction of TGF-β1, by virions and/or by free gp120, may interfere with immunoglobulin production, isotype switching, affinity maturation and the generation of both plasma B cells and memory B cells, all of which are strictly dependent on B cell proliferation 39, 47, 48 . Of note, a role for integrins in the regulation of TGF-β1 has been described 49 . In support of the relevance of that potential mechanism of B cell dysfunction in vivo, it has been reported that plasma from viremic people has much higher TGF-β1 concentrations 50, 51 .
Exposure of B cells to gp120 induced a second protein associated with B cell dysfunction: FcRL4, an inhibitory receptor for IgA that is normally found on B cells in the GALT 33, 52 . Moreover, gp120 potentiated the induction of FcRL4 expression on B cells stimulated by T cellindependent or T cell-dependent inductive signals. In HIV-1-infected viremic people, FcRL4 is overexpressed on circulating B cells 10 . Its expression is linked to inhibition of B cell proliferation in a manner that is not fully understood. Although it is unclear how overexpression of FcRL4 affects B cell function, the ability of gp120 to induce its expression is consistent with the FcRL4 overexpression on B cells of chronically HIV-infected viremic people. Of note, we found that treatment of B cells with TGF-β1 induced FcRL4 expression. Notably, the gp120-mediated block of proliferation and induction of FcRL4 expression was abrogated by the inclusion of a TGF-β1-neutralizing mAb. Thus, the induction of FcRL4 was a result of gp120-mediated induction of TGF-β1 expression. In this context, we also found that coculture of B cells with autologous HIV-1-infected CD4 + T cells induced the B cells to upregulate FcRL4 expression, in support of the proposal of a direct link among viremia, induction of TGF-β1 expression and upregulation of FcRL4 expression. That finding is relevant not only for the HIV-1 field but also for understanding the role of TGF-β1 and FcRL4 in the activation and proliferation of B cells.
The binding of gp120 to B cells not only impairs the activation and proliferation of naive B cells but also affects their ability to function as antigen-presenting cells by preventing cell-surface expression of CD80. Aberrant expression of CD80 and CD86 in HIV-1-infected, viremic people has been reported 6 . Such defects probably contribute to the lack of an efficient humoral response in HIV-1-infected people. When B cells isolated from healthy people are stimulated in vitro, the expression of both CD80 and CD86 is induced, but B cells derived from HIV-1-infected, viremic people fail, after stimulation, to upregulate 
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A r t i c l e s expression of those costimulatory receptors 6 . In addition, CD80 expression is lower in germinal center B cells from viremic people 36 . We found a similar response in B cells exposed to gp120 in vitro, such that stimulated B cells upregulated CD80 expression in the absence of gp120 but not in its presence. Treatment of B cells with gp120 in vitro modulated CD80 expression in a manner similar to the way in which viremia affects CD80 expression. Like gp120-mediated induction of FcRL4 expression, the lower surface expression of CD80 depended on TGF-β1 production.
In summary, we have demonstrated that gp120 bound directly to α 4 β 7 on primary B cells and that this interaction recapitulated certain phenotypic and functional abnormalities of B cells from HIV-1-infected, viremic people. It is likely that some of those defects are linked to the aberrant activation of the immune system associated with the viremia of HIV-1 infection. Indeed, polyclonal B cell activation and poor T cell help can be correlated with aberrant activation of the immune system in viremic people 2 . However, many of those defects are transient, as they are reversed by antiretroviral therapy 7 . Therefore, it is reasonable to postulate that certain aspects of the defective humoral response in HIV-infected people 7, 16 result from direct interactions between virions and/or free gp120 and B cells 25, 53 . Coincident with hyperactivation of B cells, patients exhibit defects in mucosal IgA responses and a delay in virus-specific antibody affinity maturation 20, 54 . The data presented here have shown that virions and/or free gp120 directly impaired the activation and proliferation of naive B cells by releasing TGF-β1, which in turn upregulated expression of the inhibitory IgA receptor FcRL4. Of note, FcRL4 overexpression induced by gp120 may account for the inadequate mucosal IgA responses demonstrated during acute infection with HIV-1 or simian immunodeficiency virus 20, [55] [56] [57] [58] . Because viremia usually peaks during acute infection, it is at this stage of HIV-1-associated disease that the effect of gp120 on the function of naive B cells is probably most pronounced. In particular, gp120 may blunt and delay the nascent humoral immune response to HIV-1, including the generation of high-affinity HIV-specific neutralizing antibodies 47 . Thus, we propose that the B cell dysfunction that occurs during the early stages of HIV-1 infection may be caused by direct interaction of gp120 with B cells, which would explain at least in part the perplexing inadequacy of the initial humoral immune response to infection with HIV-1.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. GEO: microarray data, GSE49019. 
